| Identification | Back Directory | [Name]
ACT-132577 | [CAS]
1103522-45-7 | [Synonyms]
ACT-132577
Aprocitentan
Despropyl Macitentan
Macitentan ACT-132577
Macitentan Impurity 07
N-Despropyl Macitentan
Macitentan ACT-132577-D4
Macitentan N-Despropyl Impurity
APROCITENTAN; ACT-132577; ACT 132577; ACT132577; DESPROPYL MACITENTAN
N-[5-(4-bromophenyl)-6-[2-(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl
5-(4-BROMOPHENYL)-4-[2-(5-BROMOPYRIMIDIN-2-YL)OXYETHOXY]-6-(SULFAMOYLAMINO)PYRIMIDINE
N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]sulfamide
5-(4-bromophenyl)-6-[2-(5-bromopyrimidin-2-yl)oxyethoxy]-N-(sulfamoyl)pyrimidin-4-amine
Sulfamide, N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]- | [Molecular Formula]
C16H14Br2N6O4S | [MDL Number]
MFCD28155267 | [MOL File]
1103522-45-7.mol | [Molecular Weight]
546.19 |
| Chemical Properties | Back Directory | [Melting point ]
139-141°C | [Boiling point ]
705.0±70.0 °C(Predicted) | [density ]
1.841±0.06 g/cm3(Predicted) | [storage temp. ]
-20°C Freezer | [solubility ]
Chloroform (Slightly, Heated), Methanol (Slightly, Heated) | [form ]
Solid | [pka]
13.56±0.60(Predicted) | [color ]
White to Off-White | [InChI]
InChI=1S/C16H14Br2N6O4S/c17-11-3-1-10(2-4-11)13-14(24-29(19,25)26)22-9-23-15(13)27-5-6-28-16-20-7-12(18)8-21-16/h1-4,7-9H,5-6H2,(H2,19,25,26)(H,22,23,24) | [InChIKey]
DKULOVKANLVDEA-UHFFFAOYSA-N | [SMILES]
S(NC1C(C2=CC=C(Br)C=C2)=C(OCCOC2=NC=C(Br)C=N2)N=CN=1)(N)(=O)=O |
| Hazard Information | Back Directory | [Uses]
N-Despropyl-macitentan, is an active metabolite which is part of a family of endothelin receptor antagonist that allows for treatment of pulmonary arterial hypertension (PAH) | [Definition]
ChEBI: ACT-132577 is a member of the class of sulfamides in which one of the amino groups of sulfonamide is substituted by a 5-(4-bromophenyl)-6-{2-[(5-bromopyrimidin-2-yl)oxy]ethoxy}pyrimidin-4-yl group. An active metabolite of macitentan (obtained by oxidative depropylation), an orphan drug used for the treatment of pulmonary arterial hypertension. It has a role as an antihypertensive agent, an endothelin receptor antagonist, a drug metabolite and a xenobiotic metabolite. It is an aromatic ether, an organobromine compound, a member of pyrimidines and a member of sulfamides. It is functionally related to an ethylene glycol. | [in vivo]
Aprocitentan (ACT-132577) has a volume of distribution greater than the plasma volume and a longer half-life than its parent compound in the rat[1]. In rat plasma, the mean recovery of Aprocitentan (ACT-132577) ranges from 82.6% to 90.6%, matrix effect of Aprocitentan (ACT-132577) in rat plasma ranges from 101.4% to 115.2%[2]. | [IC 50]
ETA: 3.4 nM (IC50); ETA: 6.7 (pA2); ETB: 987 nM (IC50); ETB: 5.5 (pA2) | [storage]
Store at -20°C |
|
| Company Name: |
LETOPHARM LIMITED
|
| Telephone: |
+86-21-5821 5861 |
| Website: |
www.letopharm.com |
|